
Mariangela Ciccarese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1875867/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor–Positive Advanced Breast Cancer (EVERMET). Clinical Cancer Research, 2021, 27, 3443-3455.	7.0	4
2	Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. Breast Care, 2020, 15, 30-37.	1.4	0
3	A multicenter phase II trial of nabâ€paclitaxel and capecitabine in HERâ€2 negative and triple―negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?. Breast Journal, 2020, 26, 1857-1859.	1.0	0
4	Pharmacotherapeutic options for patients with refractory breast cancer. Expert Opinion on Pharmacotherapy, 2019, 20, 851-861.	1.8	3
5	An update on first line therapies for metastatic breast cancer. Expert Opinion on Pharmacotherapy, 2018, 19, 243-252.	1.8	8
6	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91.	2.2	27
7	Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study. Oncotarget, 2018, 9, 31877-31887.	1.8	4
8	Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. Breast Cancer Research and Treatment, 2017, 163, 587-594.	2.5	9
9	Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. Breast, 2016, 29, 24-30.	2.2	9
10	A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. Future Oncology, 2016, 12, 2589-2602.	2.4	6